Sourav Bandyopadhyay was a tenured professor at University of California, San Francisco and associate director of the cancer center when...
Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery
Listen to this article
Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.
Candid conversations with C-suite leaders.
More from New Science
• By
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
• By
Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
• By
Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.
• By
Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.